Cargando…

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a number of chronic inflammatory diseases; accordingly, baricitinib has been studied and approved for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bieber, Thomas, Feist, Eugen, Irvine, Alan D., Harigai, Masayoshi, Haladyj, Ewa, Ball, Susan, Deberdt, Walter, Issa, Maher, Grond, Susanne, Taylor, Peter C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443639/ https://www.ncbi.nlm.nih.gov/pubmed/36063279 http://dx.doi.org/10.1007/s12325-022-02281-4

Ejemplares similares

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
por: Bieber, Thomas, et al.
Publicado: (2023)

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
por: Taylor, Peter C., et al.
Publicado: (2023)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
por: Taylor, Peter C, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2023)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

Emerging Role of Baricitinib in Dermatology Practice: All We Need to Know!
por: Dogra, Sunil, et al.
Publicado: (2023)

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
por: Thyssen, Jacob P., et al.
Publicado: (2023)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
por: Ciciriello, Sabina, et al.
Publicado: (2023)

Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials
por: Fautrel, Bruno, et al.
Publicado: (2023)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials
por: Salvarani, Carlo, et al.
Publicado: (2021)

Specialized dermatological-rheumatological patient management improves diagnostic outcome and patient journey in psoriasis and psoriatic arthritis: a four-year analysis
por: Ziob, Jana, et al.
Publicado: (2021)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Foreword: Seminars in Research 2014 Joint Experiences in Rheumatology and Dermatology
por: Costanzo, Antonio, et al.
Publicado: (2016)

Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis
por: Werth, Victoria P., et al.
Publicado: (2021)

Oral health in patients with severe inflammatory dermatologic and rheumatologic disease
por: Kiernan, Yvonne, et al.
Publicado: (2022)

Exploring Dermatomyositis through an Interdisciplinary Lens: Pearls from Dermatology and Rheumatology
por: Kassamali, Bina, et al.
Publicado: (2021)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: Results from the Institute of Rheumatology Rheumatoid Arthritis cohort study
por: Nakayama, Masanori, et al.
Publicado: (2020)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Towards a combined pediatric rheumatology-dermatology clinic: One-year experience
por: Demirkan, Fatma Gul, et al.
Publicado: (2020)

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
por: King, Brett, et al.
Publicado: (2021)

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
por: Koike, Ryuji, et al.
Publicado: (2009)

Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines
por: Busger op Vollenbroek, Felien T. M., et al.
Publicado: (2018)

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology
por: Jessica Chang, Ting Yi, et al.
Publicado: (2020)

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN
por: López-Romero, Pedro, et al.
Publicado: (2020)

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
por: Yosipovitch, Gil, et al.
Publicado: (2022)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Should children with psoriasis be consulted to a rheumatologist? Result from pediatric rheumatology-dermatology collaboration
por: Karadag, Serife Gul, et al.
Publicado: (2023)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

IMPACT OF THE COVID PANDEMIC ON RHEUMATOLOGY PATIENTS IN NORTHERN IRELAND - A WEB BASED CROSS-SECTIONAL SURVEY OF PATIENT REPORTED OUTCOMES
por: McKee, Patrick, et al.
Publicado: (2021)

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials
por: Wollenberg, Andreas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9buo0eh4kreavkf9u9ksv3ka7i